½ÃÀ庸°í¼­
»óǰÄÚµå
1396554

¼¼°è ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ½ÃÀå - À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº° ¿¹Ãø(2023-2032³â)

Bioinformatics Services Market - Type (Sequencing Services, Data Analysis), Application (Genomics, Proteomics, Pharmacogenomics), End-use, (Academic Institutes & Research Centers, Hospitals & Clinics), Global Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ½ÃÀåÀº »ý¹°ÇÐÀû µ¥ÀÌÅÍ ºÐ¼®¿¡ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ÅøÀÇ Ã¤¿ëÀÌ È®´ëµÇ°í Àֱ⠶§¹®¿¡ 2023³âºÎÅÍ 2032³â±îÁöÀÇ CAGRÀÌ 15.9%°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

Á¤¹ÐÀÇ·á ¹× °³ÀÎÈ­ Ä¡·á Àü·«ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó, Á¦¾à ±â¾÷°ú »ý¸í °øÇÐ ±â¾÷Àº º¹ÀâÇÑ °Ô³ð µ¥ÀÌÅÍ¿Í ÇÁ·ÎÅ×¿È µ¥ÀÌÅ͸¦ ÇØ¼®Çϱâ À§ÇÑ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

2023³â 12¿ù, ÁÖ¿ä ¼ÒÈ­±â°è ÀÇ·á±â¾÷ÀÎ Cyted»ç´Â È£»ê±¸¼º ½Äµµ¿°(EoE)ÀÇ Áø´Ü ¹× Ä¡·á ¹ÝÀÀ ¿¹ÃøÀ» À§ÇÑ Á¤¹ÐÀÇ·á ÇÁ·ÎÁ§Æ®¸¦ À̲ø±â À§ÇØ Innovate UK»ç·ÎºÎÅÍ 100¸¸ ÆÄ¿îµåÀÇ º¸Á¶±ÝÀ» ȹµæÇß½À´Ï´Ù.

¶ÇÇÑ »ý¸í°úÇÐ ºÐ¾ß¿¡¼­ÀÇ Á¶»ç¿¬±¸È°µ¿ÀÇ È°¼ºÈ­°¡ °Ô³ð¿¬±¸¸¦ ÃßÁøÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÇÔ²² ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ½ÃÀåÀº À¯Çü, ¿ëµµ, ÃÖÁ¾ ¿ëµµ, Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.

µ¥ÀÌÅÍ ºÐ¼® ºÐ¾ß´Â »ý¹°ÇÐÀû µ¥ÀÌÅͷκÎÅÍ ÀÇ¹Ì ÀÖ´Â Áö½ÄÀ» ÃßÃâÇϱâ À§ÇÑ ±¤¹üÀ§ÇÑ ÄÄÇ»ÆÃ ±â¼úÀ» Æ÷ÇÔÇϱ⠶§¹®¿¡ 2023³âºÎÅÍ 2032³â±îÁö °­ÇÑ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀΰøÁö´É°ú ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀÇ ÅëÇÕÀº µ¥ÀÌÅÍ ºÐ¼®ÀÇ È¿À²¼º°ú Á¤È®¼ºÀ» Çâ»ó½Ã۰í Å« Çõ½Å¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ ÁøÈ­´Â ´ë±Ô¸ð »ý¹°ÇÐÀû µ¥ÀÌÅÍ ¼¼Æ®¿¡¼­ ½Ç¿ëÀûÀÎ ÅëÂû·ÂÀ» µµÃâÇÏ·Á´Â ¿¬±¸ÀÚ¿Í ÀÓ»óÀÇ¿¡°Ô ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÇÁ·ÎÅ׿À¹Í½º ¿ëµµ´Â ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º°¡ ´Ü¹éÁúÀÇ º¹ÀâÇÑ ±¸Á¶¿Í ±â´ÉÀ» ÇØ¸íÇÏ´Â µ¥ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ 2032³â±îÁö ½ÃÀå¿¡ °Å¾×ÀÇ ¼öÀÍÀ» °¡Á®¿Ã °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ´Ü¹éÁú ½Äº°, Ư¼ºÈ­ ¹× Á¤·®È­¸¦ À§ÇÑ ´Ù¾çÇÑ ¼Ö·ç¼ÇÀ» »ç¿ëÇÒ ¼ö ÀÖ°Ô µÊÀ¸·Î½á ¿¬±¸ÀÚµéÀº Áúº´ ¸ÞÄ¿´ÏÁò, ¾à¹° ¾à¹° ¹× ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¿¡ ´ëÇÑ ±íÀº ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÇÁ·ÎÅ׿À¹Í½º ºÐ¾ß´Â â¾à°ú ¾àÁ¦ °³¹ß °úÁ¤ÀÇ ÁøÀü¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ °ßÁ¶ÇÑ ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

À¯·´ÀÇ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º »ê¾÷Àº »ý¸í°úÇÐ ¿¬±¸°³¹ßÀ» À§ÇÑ °ß°íÇÑ ÀÎÇÁ¶ó¸¦ ¹è°æÀ¸·Î 2032³â±îÁö Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼±µµÀû ÀÎ »ý¸í °øÇÐ ¹× Á¦¾à ȸ»ç°¡ Á¸ÀçÇϸç Á¤ºÎ Áö¿ø Á¤Ã¥°ú ÀÚ±Ý Áö¿ø ÀÌ´Ï¼ÅÆ¼ºêµµ ÇÔ²² À¯·´Àº ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º Á¦°ø ¾÷üÀÇ Çãºê·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â Çмú±â°ü, ¿¬±¸±â°ü, ±â¾÷ °£ÀÇ Çù·ÂÀÌ ±ÞÁõÇϰí, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¿ëµµÀÇ Çõ½ÅÀÌ ÃËÁøµÇ¾î ¾÷°èÀÇ Àü¸ÁÀÌ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ¾÷°è ÀλçÀÌÆ®

  • »ê¾÷ ±¸ºÐ
  • ¾÷°è Á¤¼¼ : 2018-2032³â
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • °Ô³ð ½ÃÄö½Ì ±â¼úÀÇ Áøº¸
      • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • Á¤ºÎ·ÎºÎÅÍÀÇ ÀÚ±Ý ¿øÁ¶¿Í °øµ¿ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
      • ¼ÒÇÁÆ®¿þ¾îÀÇ °íºñ¿ë°ú °í¾× ÅõÀÚÀÇ Çʿ伺
      • ±Þ¼ÓÇÑ ±â¼úÀÇ Áøº¸¿Í º¯È­¿¡ ÀÇÇØ ƯÁ¤ ¼­ºñ½º°¡ ÁøºÎÈ­ÇÒ °¡´É¼º
  • ¼ºÀå ÀáÀç·Â ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ±â¼ú Àü¸Á
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ½ÃÀå : À¯Çüº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : À¯Çüº°
  • ½ÃÄö½Ì ¼­ºñ½º
  • µ¥ÀÌÅÍ ºÐ¼®
  • â¾à ¼­ºñ½º
  • Â÷µî À¯ÀüÀÚ ¹ßÇö ºÐ¼®
  • µ¥ÀÌÅͺ£À̽º °ü¸® ¼­ºñ½º
  • ±âŸ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º

Á¦6Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ½ÃÀå : ¿ëµµº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ¿ëµµº°
  • À¯ÀüüÇÐ
  • ´Ü¹éÁú À¯ÀüÁ¤º¸ÇÐ
  • È­ÇÐÁ¤º¸ÇÐ ¹× ¾à¹° µðÀÚÀÎ
  • °Ô³ð¾àÇÐ
  • Àü»çüÇÐ
  • ´ë»çüÇÐ
  • ±âŸ ¿ëµµ

Á¦7Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ½ÃÀå : ÃÖÁ¾ ¿ëµµº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾ ¿ëµµº°
  • Çмú±â°ü ¹× ¿¬±¸¼Ò
  • º´¿ø ¹× Ŭ¸®´Ð
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • CRO(ÀǾàǰ °³¹ß ¾÷¹« ¼öŹ ±â°ü)
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦8Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ½ÃÀå : Áö¿ªº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ±âŸ MEA

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Illumina, Inc.
  • BGI
  • Thermo Fisher Scientific Inc.
  • PerkinElmer Inc.
  • Eurofins Scientific
  • NeoGenomics
  • CD Genomics
  • Macrogen
  • QIAGEN(QIAGEN NV)
  • GENEWIZ
  • Source BioScience
  • Microsynth
  • MedGenome
  • Fios Genomics
  • BaseClear
JHS 23.12.27

Bioinformatics services market is predicted to observe 15.9% CAGR from 2023 to 2032 due to the growing adoption of bioinformatics tools for the analysis of biological data. With the escalating need for precision medicine and personalized treatment strategies, pharmaceutical and biotechnology companies are increasingly relying on bioinformatics services to interpret complex genomic and proteomic data.

In December 2023, Cyted, a leading gastrointestinal health firm, obtained a £1 million grant from Innovate UK to spearhead a precision medicine project for Eosinophilic Esophagitis (EoE) diagnosis and treatment response prediction.

Moreover, the rise in R&D activities in the life sciences sector, coupled with government initiatives promoting genomics research, is fostering market growth.

The bioinformatics services market is classified based on type, application, end-use, and region.

The data analysis segment is expected to record strong CAGR from 2023 to 2032 as it encompasses a wide array of computational techniques to extract meaningful insights from biological data. This is influencing significant innovation, with the integration of artificial intelligence and machine learning algorithms enhancing the efficiency & accuracy of data interpretation. This evolution is pivotal for researchers and clinicians aiming to derive actionable insights from large-scale biological datasets.

The proteomics application will generate massive revenues for the market by 2032 as bioinformatics services help in unraveling the complexities of protein structures and functions. The availability of various solutions for protein identification, characterization, and quantification, is enabling researchers to gain deeper insights into disease mechanisms, drug targets, and biomarker discovery. The proteomics segment is anticipated to witness robust growth owing to its pivotal role in advancing drug discovery and development processes.

Europe bioinformatics services industry is anticipated to grow significantly through 2032 driven by the region's robust infrastructure for life sciences R&D. The presence of leading biotechnology and pharmaceutical companies, coupled with supportive government policies and funding initiatives, positions Europe as a hub for bioinformatics service providers. The region is witnessing a surge in collaborations between academic institutions, research organizations, and industry players, fostering innovation in bioinformatics applications, thereby shaping the industry outlook.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition & scope
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 COVID-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Global bioinformatics services industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Type trends
    • 2.1.4 Application trends
    • 2.1.5 End-use trends

Chapter 3 Bioinformatics Services Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2018 - 2032 (USD Million)
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Advancements in genomic sequencing technologies
      • 3.3.1.2 Increasing demand for personalized medicine
      • 3.3.1.3 Government fundings and collaborative research initiatives
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 High cost of software and need for high investments
      • 3.3.2.2 Rapid technological advancements and changes may render certain services obsolete
  • 3.4 Growth potential analysis
    • 3.4.1 By type
    • 3.4.2 By application
    • 3.4.3 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Technology landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive analysis of major market players, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategic dashboard, 2022

Chapter 5 Bioinformatics Services Market, By Type, 2018 - 2032 (USD Million)

  • 5.1 Key trends, by type
  • 5.2 Sequencing services
  • 5.3 Data analysis
  • 5.4 Drug discovery services
  • 5.5 Differencial gene expression analysis
  • 5.6 Database management services
  • 5.7 Other bioinformatics services

Chapter 6 Bioinformatics Services Market, By Application, 2018 - 2032 (USD Million)

  • 6.1 Key trends, by application
  • 6.2 Genomics
  • 6.3 Proteomics
  • 6.4 Chemoinformatics & drug design
  • 6.5 Pharmacogenomics
  • 6.6 Transcriptomics
  • 6.7 Metabolomics
  • 6.8 Other applications

Chapter 7 Bioinformatics Services Market, By End-use, 2018 - 2032 (USD Million)

  • 7.1 Key trends, by end-use
  • 7.2 Academic institutes & research centers
  • 7.3 Hospitals & clinics
  • 7.4 Pharmaceutical and biotechnology companies
  • 7.5 Contract Research Organization (CROs)
  • 7.6 Other end-users

Chapter 8 Bioinformatics Services Market, By Region, 2018 - 2032 (USD Million)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 MEA
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Rest of MEA

Chapter 9 Company Profiles

  • 9.1 Illumina, Inc.
  • 9.2 BGI
  • 9.3 Thermo Fisher Scientific Inc.
  • 9.4 PerkinElmer Inc.
  • 9.5 Eurofins Scientific
  • 9.6 NeoGenomics
  • 9.7 CD Genomics
  • 9.8 Macrogen
  • 9.9 QIAGEN (QIAGEN N.V.)
  • 9.10 GENEWIZ
  • 9.11 Source BioScience
  • 9.12 Microsynth
  • 9.13 MedGenome
  • 9.14 Fios Genomics
  • 9.15 BaseClear
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦